尼洛替尼诱导了一名为慢性髓性白血病治疗的患者的大型心周输液
Muhammad Hasan1, Melanie LaVoie2,3
1Internal Medicine Residency Program, University of South Dakota Sanford School of Medicine.
尼罗丁尼改善慢性髓性白血病的结果,但很少引起心周溢出. 本病例报告详细介绍了这种不良反应在接受尼洛尼治疗的患者中罕见的一例.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 尼洛替尼是一种铁氨酸激酶抑制剂 (TKI),用于费城染色体阳性 (Ph +) 慢性髓性白血病 (CML).
- 技术技巧针对BCR-ABL1融合蛋白,改善CML治疗结果.
- 目标外的激酶抑制可以导致不良副作用.
更多相关视频
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
14:04Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents
Published on: March 25, 2016
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Heart Failure Drugs: Inotropic Agents
Pericarditis IV: Nursing Management
Targeted Cancer Therapies
There are several types of targeted therapies against...
Myocarditis IV: Nursing Management
